KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Efficacy and safety of cAMP signalling-biased GLP-1 analogue ecnoglutide monotherapy versus placebo in patients with type 2 diabetes (EECOH-1): a multi-centre, randomised, double-blind, placebo-controlled, phase 3 trial.

Dalong Zhu, Weimin Wang, Guoyu Tong, Jianhua Ma, Binhong Wen, Xin Zheng, Bimin Shi, Shuguang Pang, Kun Wang, Xiaoxia Shi, Xianghua Zhang, Liujun Fu, Yang Liu, Yibing Lu, Debin Huang, Chengxia Jiang, Tianrong Pan, Haibo Xue, Jie Han, Hongcheng Ding, Shaohui Bing, Feifei Jiang, Qing Zheng, Ming Yang, Lei Guan, Xingquan Liu, Jing Ning, Yue Bu, Mengying Guo, Liu Yang, Wanjun Guo, Yao Li, Susan Xu, Hai Pan

Nat Commun 17(1) 1420

PMID41501026
PMCIDPMC12881390
DOI10.1038/s41467-025-68165-7
发表日期2026-01-07
入排依据:未发现恶性肿瘤人群证据。
已检查 2 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 flow diagram;Fig. 2:AI 判定为 other。
摘要

摘要

Ecnoglutide is a cAMP-biased GLP-1 analogue developed for the treatment of type 2 diabetes mellitus (T2DM) and obesity. We conducted a randomised, double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy and safety of ecnoglutide in adults with T2DM inadequately controlled with diet and exercise alone or with a single oral hypoglycaemic agent. The primary endpoint was change in glycated haemoglobin (HbA1c) from baseline at week 24. Between 29 December 2022 and 12 June 2024, 211 participants from 32 medical centres in China were randomised (2:2:1:1) to receive double-blind, once-weekly ecnoglutide (0.6 mg [n = 69] or 1.2 mg [n = 71]) or volume-matched placebo (0.6 mg [n = 36] or 1.2 mg [n = 35]) for 24 weeks. The randomisation, stratified by baseline HbA1c (≤8.5% or >8.5%), was conducted via an interactive web response system. Ecnoglutide and placebo were identical in appearance to achieve masking. The trial was completed. All randomised participants received ≥1 dose of the assigned treatment and thus were included for analyses. At week 24, the least squares mean changes from baseline in HbA1c were -1.96% (95% CI -2.18 to -1.73) with ecnoglutide 0.6 mg and -2.43% (95% CI -2.65 to -2.20) with ecnoglutide 1.2 mg versus -0.87% (-1.09 to -0.65) with placebo. The estimated treatment differences versus placebo were -1.09% (95% CI -1.40 to -0.77; p = 0.0003) with ecnoglutide 0.6 mg and -1.56% (95% CI -1.87 to -1.24; p < 0.0001) with ecnoglutide 1.2 mg. Ecnoglutide represents a potential monotherapy option for T2DM. This trial was registered at clinicaltrials.gov with the registration number NCT05680155.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1. Trial profile. Notes: a One participant who had a pre-dose adverse event during the run-in period and was not randomised. b Three participants who did not enter the open-label study after 24 weeks of the double-blind treatment due to rescue therapy were considered as completing the trial according to the protocol. c One participant discontinued treatment because of decreased appetite.
非 KM Figure
Fig. 2Fig. 2. Efficacy outcomes of 0.6 mg and 1.2 mg ecnoglutide once weekly versus placebo at weeks 24 and 52. Data are mean (SD), unless otherwise noted, and participants in the placebo groups switched to ecnoglutide after week 24. A Change from baseline in HbA 1c over time. B Change from baseline in HbA 1c at week 24 from MMRM analysis (estimated treatment differences are LSM [95% CI] at week 24 [full analysis set] and p -values were obtained from two-sided t-tests with multiplicity adjusted). C Proportion of participants reaching HbA 1c targets (<7.0%, ≤6.5%, and <5.7%) and the composite endpoint (HbA 1c < 7.0%, no severe hypoglycaemia, and no bodyweight gain) analysis at week 24. D Change from baseline in FPG over time. E Seven-point SMBG profiles at baseline and week 24. F Change from baseline in bodyweight over time. Source data are provided as a Source Data file. CI = confidence interval. FPG = fasting plasma glucose. HbA 1c = glycated haemoglobin. LSM = least squares mean. MMRM = mixed model for repeated measures. SD = standard deviation. SMBG = self-monitored blood glucose.
非 KM Figure